Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Non-Invasive Measurement of GI Motility in Patients With ALS
Recent evidence implicates abnormalities of autonomic function in ALS including problems
with gastrointestinal (GI) motility. GI complaints reported by ALS patients such as
constipation, diffuse abdominal pain, and a feeling of fullness or nausea may be attributed
to autonomic involvement. Toepfer et al. found delayed gastric emptying in most ALS
patients, indicating autonomic dysfunction (Gastrointestinal dysfunction in amyotrophic
lateral sclerosis. Amyotrophic Lateral Sclerosis Other Motor Neuron Disord 1999; 1:15—19).
The same authors also reported markedly prolonged colon transit time in ALS (Toepfer et al:
Delayed colonic transit times in amyotrophic lateral sclerosis assessed with radio-opaque
markers. Eur J Med Res 1997; 2:473—476).
The present study will investigate the GI transit time in a large cohort of patients and
controls using a noninvasive technique that measure hydrogen gas production with the
digestion of lactulose in a measured substrate load presented to the bowel.
This study will examine how much time it takes for the food to travel along the intestines
from mouth or stomach (if you have a feeding tube) to the end of the large intestine using a
special instrument that measures hydrogen gas in your breath. Data collection will start
after you sign this consent form. The only procedures that would be above and beyond routine
care are indicated below:
In order to prepare for the study you will be asked to be off all medications that affects
the GI motility for 24 hours. You will also be asked to fast overnight (starting midnight)
the day before the test.
After fasting overnight, the test will be performed in the morning (at the Neurology
Outpatient Clinic or at your home). Before eating or drinking anything a baseline
measurement will be taken by breathing into the hydrogen meter. This will be just normal
breathing. You will then drink a test meal consisting of 250 ml (approximately 1 cup) of a
lactose (type of sugar) free supplement (For example Ensure) that has 20 grams of Lactulose
added. If you have a peg tube then the supplement will be given through the tube. After 10
minutes you will again be asked to breath into the machine to measure the hydrogen gas
levels. This will be repeated every 10 minutes until the hydrogen levels rise to a certain
level or until 4 hours have passed.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
| Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
| Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
| Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
| Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
| Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
| Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
| Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
| Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
| Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
| Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
| Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
| Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
| Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
| Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |